Logo

Cenix BioScience Providing RNAi Services to Schering

Feb 28, 2005

NEW YORK, Feb. 28 (GenomeWeb News) - Cenix BioScience of Dresden, Germany is providing Schering with RNA interference research services to prioritize drug targets, Cenix said today.

 

Under two projects, which began at the end of 2004, Cenix has been validating candidate genes for drug targets provided by Schering using high-throughput RNAi and high-content phenotype analyses in human and mouse cell lines.

 

The companies disclosed neither the disease areas nor financial terms of the agreement.

Breaking News
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.